Adicet Bio, Inc. (ACET) Revenue History
Annual and quarterly revenue from 2008 to present
ACET Revenue Over Time (2008–2025)
ACET Revenue Growth History
9 of 15 years with positive growth- FY2008 revenue growth
- N/A
- FY2009 revenue growth
- -10.3%
- FY2010 revenue growth
- +7.4%
- FY2011 revenue growth
- +19.0%
- FY2012 revenue growth
- +7.7%
- FY2013 revenue growth
- +12.4%
- FY2014 revenue growth
- +0.0%
- FY2015 revenue growth
- +2.1%
- FY2016 revenue growth
- +7.2%
- FY2017 revenue growth
- +2.1%
- FY2018 revenue growth
- -98.5%
- FY2019 revenue growth
- -87.8%
- FY2020 revenue growth
- +1699.3%
- FY2021 revenue growth
- -45.7%
- FY2022 revenue growth
- +156.8%
- FY2023 revenue growth
- -100.0%
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2017)
ACET's revenue distribution by segment and geography for fiscal year 2017
By Product/Segment
By Geography
ACET Revenue Analysis (2008–2025)
Current Revenue & Growth
As of June 13, 2026, Adicet Bio, Inc. (ACET) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
ACET's historical revenue data shows various trends over time. Adicet Bio, Inc.'s highest annual revenue of $558.5 million was recorded in 2017.
Revenue by Segment
ACET's revenue is primarily driven by Human Health (49%), Performance Chemicals (26%), and Pharmaceutical Ingredients (25%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including FATE (-52.6% YoY), TCRX (+106.7% YoY), and IOVA (+34.3% YoY). Compare ACET vs FATE →
ACET Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 ACETCurrent | $0 | - | - | - | |
 FATE | $7M | -52.6% | -26.7% | -2222.4% | |
 TCRX | $10M | +106.7% | +56.9% | -1315.4% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 NTLA | $68M | +45.0% | +3.1% | -651.7% |
ACET Historical Revenue Data (2008–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-6,381,000 | - | $-122,114,000 | - |
| 2024 | $0 | - | $0 | - | $-127,615,000 | - |
| 2023 | $0 | -100.0% | $0 | - | $-152,038,000 | - |
| 2022 | $25.0M | +156.8% | $25.0M | 100.0% | $-72,551,000 | -290.3% |
| 2021 | $9.7M | -45.7% | $9.7M | 100.0% | $-61,433,000 | -631.4% |
| 2020 | $17.9M | +1699.3% | $17.9M | 100.0% | $-39,191,000 | -218.9% |
| 2019 | $995K | -87.8% | $995K | 100.0% | $-31,388,000 | -3154.6% |
| 2018 | $8.2M | -98.5% | $8.1M | 99.0% | $-14,964,000 | -182.9% |
| 2017 | $558.5M | +2.1% | $558.5M | 100.0% | $-18,882,000 | -3.4% |
| 2016 | $547.0M | +7.2% | $135.4M | 24.8% | $-1,000 | -0.0% |
| 2015 | $510.2M | +2.1% | $114.7M | 22.5% | $44.3M | 8.7% |
| 2014 | $499.7M | +0.0% | $98.3M | 19.7% | $34.4M | 6.9% |
| 2013 | $499.7M | +12.4% | $98.3M | 19.7% | $34.4M | 6.9% |
| 2012 | $444.4M | +7.7% | $82.0M | 18.5% | $25.4M | 5.7% |
| 2011 | $412.4M | +19.0% | $65.8M | 16.0% | $16.6M | 4.0% |
What if you invested $1,000 in ACET back in 2008?
Total return with dividends reinvested · 18+ years of data
Calculate ReturnsHow much would $100/month in ACET be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ACET Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationACET vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowACET — Frequently Asked Questions
Quick answers to the most common questions about buying ACET stock.
Is ACET's revenue growth accelerating or slowing?
ACET TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ACET's revenue history from 2008 to 2026?
Adicet Bio, Inc. (ACET) revenue history spans 2008 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ACET's long-term revenue growth rate (CAGR)?
Adicet Bio, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ACET.
Why does ACET's quarterly revenue fluctuate?
ACET quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Adicet Bio, Inc.'s revenue data from 2008 to 2026 shows full historical quarterly detail on this page.
How is ACET's revenue distributed by segment?
ACET reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ACET's revenue compare to industry peers?
Adicet Bio, Inc. (ACET) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.